2022
Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
Wilson E, Young C, Ramos Benitez J, Swarovski M, Feinstein I, Vandijck M, Le Guen Y, Kasireddy N, Shahid M, Corso N, Wang Q, Kennedy G, Trelle A, Lind B, Channappa D, Belnap M, Ramirez V, Skylar-Scott I, Younes K, Yutsis M, Le Bastard N, Quinn J, van Dyck C, Nairn A, Fredericks C, Tian L, Kerchner G, Montine T, Sha S, Davidzon G, Henderson V, Longo F, Greicius M, Wagner A, Wyss-Coray T, Poston K, Mormino E, Andreasson K. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease. Alzheimer's Research & Therapy 2022, 14: 172. PMID: 36371232, PMCID: PMC9652927, DOI: 10.1186/s13195-022-01116-2.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersCognitive DysfunctionHumansTau ProteinsConceptsPlasma p-tau181Alzheimer's Disease Research CenterP-tau181Disease Research CenterAlzheimer's diseasePositron emission tomographyAD dementiaBlood-based biomarker assaysAmyloid positron emission tomographyTreatment monitoringNovel blood-based biomarkersCSF p-tau181P-tau181 concentrationsDisease-modifying therapiesAβ42/Aβ40 ratioBlood-based biomarkersClinical AD diagnosisDetection of ADMild cognitive impairmentStudy cohortCSF biomarkersPlasma levelsAD groupPrognostic performanceCDR sum
2021
Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease.
Trelle AN, Carr VA, Wilson EN, Swarovski MS, Hunt MP, Toueg TN, Tran TT, Channappa D, Corso NK, Thieu MK, Jayakumar M, Nadiadwala A, Guo W, Tanner NJ, Bernstein JD, Litovsky CP, Guerin SA, Khazenzon AM, Harrison MB, Rutt BK, Deutsch GK, Chin FT, Davidzon GA, Hall JN, Sha SJ, Fredericks CA, Andreasson KI, Kerchner GA, Wagner AD, Mormino EC. Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease. Neurology 2021, 96: e1470-e1481. PMID: 33408146, PMCID: PMC8055319, DOI: 10.1212/wnl.0000000000011477.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAgingAlzheimer DiseaseAmyloid beta-PeptidesAssociation LearningBiomarkersCross-Sectional StudiesCuesDiscrimination, PsychologicalFemaleHippocampusHumansMaleMemoryMemory DisordersMemory, EpisodicMental RecallMiddle AgedNeuropsychological TestsPeptide FragmentsPsychomotor PerformanceTau ProteinsConceptsMemory taskHippocampal functionMnemonic discrimination taskMnemonic discrimination performanceUnimpaired older adultsHippocampal-dependent memoryPreclinical Alzheimer's diseaseEpisodic memoryPreclinical AD pathologyIndividual differencesMemory assessmentMemory performanceDiscrimination taskTask difficultyAssociative memoryDiscrimination performanceSingle batch analysisCross-sectional relationshipMemory studiesOlder adultsMemoryAlzheimer's disease biomarkersCSF β-amyloidElevated p-tauRecall
2020
Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases
Mormino EC, Toueg TN, Azevedo C, Castillo JB, Guo W, Nadiadwala A, Corso NK, Hall JN, Fan A, Trelle AN, Harrison MB, Hunt MP, Sha SJ, Deutsch G, James M, Fredericks CA, Koran ME, Zeineh M, Poston K, Greicius MD, Khalighi M, Davidzon GA, Shen B, Zaharchuk G, Wagner AD, Chin FT. Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 48: 2233-2244. PMID: 32572562, PMCID: PMC7755737, DOI: 10.1007/s00259-020-04923-7.Peer-Reviewed Original ResearchConceptsStandardized uptake value ratioAlzheimer's diseaseHealthy controlsCourse of ADSemantic variant primary progressive aphasiaVariant primary progressive aphasiaNeurofibrillary tangle pathologyOlder healthy controlsUptake value ratioPrimary progressive aphasiaAnterior temporal poleMedial temporal lobeNovel PET ligandMethodsForty-nine participantsTangle pathologyTau-PETSvPPA patientsFocal uptakeEarly diagnosisSubtle elevationRobust elevationTemporal lobeHC groupProgressive aphasiaPET ligand